Zika Virus Vaccine Development: Progress in the Face of New Challenges

Zika virus (ZIKV) emerged at a global level when it spread to the Americas and began causing congenital malformations and microcephaly in 2015. A rapid response by academia, government, public health infrastructure, and industry has enabled the expedited development and testing of a suite of vaccine...

Full description

Saved in:
Bibliographic Details
Published inAnnual review of medicine Vol. 70; no. 1; pp. 121 - 135
Main Authors Diamond, Michael S, Ledgerwood, Julie E, Pierson, Theodore C
Format Journal Article
LanguageEnglish
Published United States Annual Reviews 27.01.2019
Annual Reviews, Inc
Subjects
Animal models
Animals
Antibodies, Neutralizing - immunology
antibody
antibody-dependent enhancement
Communicable Diseases, Emerging - prevention & control
Congenital defects
dengue virus
Disease Outbreaks
Drug Development
Epidemics
Female
flavivirus
Forecasting
Humans
Immunization
Male
Microencephaly
neutralization
Pathogenesis
Pregnancy
Public health
vaccine
Vaccine development
Vaccines
Vector-borne diseases
Viral Envelope Proteins - immunology
Viral Vaccines - immunology
Viruses
Zika virus
Zika Virus - immunology
Zika Virus - pathogenicity
Zika Virus Infection - epidemiology
Zika Virus Infection - immunology
Zika Virus Infection - prevention & control
ZIKV
ZIKV
vaccine
antibody
neutralization
dengue virus
Zika virus
antibody-dependent enhancement
flavivirus
Online AccessGet full text

Cover

More Information
Summary:Zika virus (ZIKV) emerged at a global level when it spread to the Americas and began causing congenital malformations and microcephaly in 2015. A rapid response by academia, government, public health infrastructure, and industry has enabled the expedited development and testing of a suite of vaccine platforms aiming to control and eliminate ZIKV-induced disease. Analysis of key immunization and pathogenesis studies in multiple animal models, including during pregnancy, has begun to define immune correlates of protection. Nonetheless, the deployment of ZIKV vaccines, along with the confirmation of their safety and efficacy, still has major challenges, one of which is related to the waning of the epidemic. In this review, we discuss the measures that enabled rapid progress and highlight the path forward for successful deployment of ZIKV vaccines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:0066-4219
1545-326X
DOI:10.1146/annurev-med-040717-051127